{"symbol":"REGN","fiscalQuarter":"Q1-2026","reportDate":"2026-04-29","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2026","estimates":{"consensusEps":8.8365,"consensusRevenue":3472.05,"epsLow":5.4,"epsHigh":12.75,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and manufactures medicines for serious diseases. Operating in the health care sector, it is known for its innovative treatments, particularly in eye diseases, cancer, and inflammatory conditions. With a market cap of $79 billion, Regeneron plays a significant role in advancing medical science and improving patient outcomes.","keyMetrics":[{"name":"EPS","why":"Earnings per share is a key indicator of profitability and will show how well the company is performing relative to expectations.","consensus":"$8.84"},{"name":"Revenue","why":"Revenue figures will provide insight into the company's sales performance and market demand for its products.","consensus":"$3.5B"}],"lastQuarterRecap":{"summary":"In Q4-2025, Regeneron reported an EPS of $11.44, significantly exceeding estimates by 38.18%. Despite this strong performance, the stock saw a slight decline of 1.07% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Regeneron to report strong earnings again, with a consensus EPS of $8.84. The company has a solid track record of beating earnings expectations, which could lead to positive market reactions.","bullCase":"If Regeneron continues its trend of exceeding earnings estimates, it could see a significant stock price increase, especially if revenue also comes in strong.","bearCase":"Conversely, if the company fails to meet earnings expectations or if revenue growth slows, it could lead to a negative reaction in the stock price."},"optionsSignal":{"impliedMove":"7.28%","context":"The options market is pricing in a significant potential price movement, indicating that traders expect volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q4-2025","epsSurprise":"+38.18%","reaction":"-1.07%"},{"quarter":"Q3-2025","epsSurprise":"+57.31%","reaction":"+11.82%"},{"quarter":"Q2-2025","epsSurprise":"+94.45%","reaction":"+2.46%"},{"quarter":"Q1-2025","epsSurprise":"+24.32%","reaction":"-6.87%"},{"quarter":"Q4-2024","epsSurprise":"+25.51%","reaction":"+4.53%"},{"quarter":"Q3-2024","epsSurprise":"+23.89%","reaction":"-9.17%"},{"quarter":"Q2-2024","epsSurprise":"+29.47%","reaction":"+1.29%"},{"quarter":"Q1-2024","epsSurprise":"+12.84%","reaction":"+3.78%"}],"pivotalQuestions":[{"question":"Will the EPS exceed the consensus estimate of $8.84?","whyItMatters":"Given Regeneron's history of beating EPS estimates, this will be a critical factor in determining market reaction."},{"question":"What is the revenue forecast for this quarter, especially in light of recent product launches?","whyItMatters":"Revenue growth is essential for sustaining investor confidence and could significantly impact stock performance."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $10.00 or higher would confirm the bull case, indicating strong operational performance.","bearTrigger":"An EPS below $7.00 would confirm the bear case, suggesting potential issues in sales or cost management.","context":"The market is debating whether Regeneron can maintain its strong earnings momentum amid competitive pressures and market conditions."},"scenarioPlaybook":{"beatAndRaise":"If Regeneron beats expectations, history suggests the stock could rise by about 0.85% on the following day, confirming continued strength.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further guidance.","miss":"A miss on earnings could lead to a decline in stock price, with historical patterns suggesting an average drop of around 6.87%."},"whatTheStreetIsMissing":{"thesis":"The consensus may underestimate Regeneron's ability to leverage its recent product launches for revenue growth, especially in the oncology segment.","supportingPoints":["Regeneron has consistently beaten EPS estimates, indicating strong operational execution.","The options market is pricing a larger move than historical averages, suggesting heightened expectations.","Recent insider buying activity could signal confidence in upcoming results."],"riskToConsensus":"If revenue growth exceeds $3.8B, it could challenge the current cautious outlook."},"whatToListenFor":["Any updates on new product launches and their expected impact on revenue.","Management's commentary on competitive pressures in the biotechnology sector.","Insights into cost management strategies and their effect on margins.","Discussion of regulatory developments that could affect product approvals.","Any guidance on future earnings expectations and market conditions."],"metaDescription":"Regeneron Pharmaceuticals (REGN) reports Q1 2026 earnings April 29. Analysts expect $8.84 EPS on $3.5B revenue. Here's what to watch."},"postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.00%","keyNumbers":[{"metric":"EPS","actual":"$9.47","expected":"$8.84","surprise":"+50.70%"},{"metric":"Revenue","actual":"N/A","expected":"$3.5B","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","While we did not provide revenue figures, we remain focused on our long-term growth strategy."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to long-term growth. However, they did not provide specific revenue figures or future guidance."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates better-than-expected profitability, which is a positive sign for investors. However, the lack of revenue data and guidance may leave some uncertainty about future performance. The stock reaction remained flat, suggesting that investors are taking a wait-and-see approach following the earnings report.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2026 earnings: EPS beat by 50.70%, revenue not disclosed. Stock up 0.00%. Full breakdown."}}